Treatment with triple combination of atorvastatin perindopril and amlodipine in patients with stable coronary artery disease: A subgroup analysis from the PAPA-CAD study

摘要

BackgroundIn patients with stable coronary artery disease, aspirin, a statin, and an angiotensin-converting enzyme inhibitor are recommended as first-line agents for secondary prevention. Subgroup analyses of the previously published Hungarian Perindopril plus Amlodipine in PAtients with Coronary Artery Disease (PAPA-CAD) non-interventional trial demonstrated that the addition of the metabolically beneficial, fixed combination of perindopril + amlodipine to atorvastatin further improves the patient’s lipid profile.